Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Neoplasms 1

Interventions

Paclitaxel 79Carboplatin 64Bevacizumab 33liposomal doxorubicin 29Topotecan 28Gemcitabine 25Cisplatin 19olaparib 18Drug Therapy 12Doxorubicin 12Taxes 11niraparib 9Docetaxel 6CP protocol 6Trabectedin 5Hyperthermic Intraperitoneal Chemotherapy 5Etoposide 5Cyclophosphamide 51-dodecylpyridoxal 5rucaparib 4pembrolizumab 4avelumab 4atezolizumab 4Immunoglobulin G 4Ifosfamide 4Disulfides 4Dexamethasone 4Chemotherapy, Adjuvant 4trebananib 3fluzoparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Ovarian Neoplasms × cositecan × Clear all
NCT00477282 2020-03-12

Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer

BioNumerik Pharmaceuticals, Inc.

Phase 3 Completed
509 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡